Shionogi & Co., Ltd.
Stock Price Chart
2026/06/11 UpdatedPrice Trend
2026/06/11 UpdatedPrice & Trading Details
2026/06/11 UpdatedPRICE
TRADING
Analyst Recommendations 11 analysts
Updated 2026/06/05Earnings Calendar
Updated 2026/06/05Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/01/29 | ¥68.45 | ¥87.76 | +28.2% |
| 2025/10/27 | ¥50.55 | ¥51.93 | +2.7% |
| 2025/07/28 | ¥42.54 | ¥46.26 | +8.7% |
| 2025/05/12 | ¥43.20 | ¥43.06 | -0.3% |
Shareholder Composition
Updated 2026/06/05Top Mutual Funds / ETFs
Updated 2026/06/05Major Holders
Updated 2026/06/05| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
18.6M | +56.76% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
11.0M | +0.84% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
7.1M | +2.20% | |
|
HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT.
|
6.5M | -10.17% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
5.4M | +0.59% | |
|
John Hancock Funds III-International Growth Fund
|
3.2M | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
465.1K | +6.79% |
Dividend History
Updated 2026/05/31| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥38 | -42.4% |
| 2025 | ¥66 | +16.5% |
| 2024 | ¥57 | +13.3% |
| 2023 | ¥50 | +25.0% |
| 2022 | ¥40 | - |
Financial Performance
2026/05/31 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥335,138M | ¥426,684M | ¥435,081M | ¥438,268M |
| Gross Profit | ¥279,722M | ¥364,437M | ¥377,479M | ¥374,441M |
| Operating Income | ¥110,312M | ¥149,004M | ¥153,312M | ¥156,604M |
| Pretax Income | ¥127,109M | ¥224,832M | ¥204,984M | ¥209,777M |
| Net Income | ¥114,185M | ¥184,965M | ¥162,030M | ¥170,435M |
| EPS | ¥126.21 | ¥207.03 | ¥186.11 | - |
| Operating Margin | 32.92% | 34.92% | 35.24% | 35.73% |
| Balance Sheet | ||||
| Total Assets | ¥1,150,601M | ¥1,311,800M | ¥1,416,918M | ¥1,535,349M |
| Total Equity | ¥975,661M | ¥1,100,046M | ¥1,235,325M | ¥1,361,924M |
| Total Liabilities | ¥174,940M | ¥211,754M | ¥181,593M | ¥173,425M |
| Cash | ¥254,420M | ¥309,224M | ¥358,090M | ¥374,795M |
| Interest-bearing Debt | ¥6,674M | ¥9,411M | ¥11,620M | ¥21,882M |
| Equity Ratio | 84.80% | 83.86% | 87.18% | 88.70% |
| D/E Ratio | 0.01 | 0.01 | 0.01 | 0.02 |
| Cash Flow | ||||
| Operating CF | ¥102,068M | ¥177,867M | ¥154,284M | ¥195,460M |
| Investing CF | -¥96,204M | -¥48,292M | ¥5,922M | -¥116,080M |
| Financing CF | -¥36,615M | -¥84,123M | -¥126,853M | -¥64,908M |
| Free CF | ¥70,504M | ¥140,680M | ¥126,017M | ¥143,357M |
| Efficiency | ||||
| ROE | 11.70% | 16.81% | 13.12% | 12.51% |
| ROA | 9.92% | 14.10% | 11.44% | 11.10% |
Latest IR Information
-
FDA Approval for New COVID-19 Treatment | Shionogi & Co., Ltd. May 2026
Shionogi & Co., Ltd. obtained FDA approval in the United States for the anti-SARS-CoV-2 drug ensitrelvir on June 16, 2026. This achievement marks the first oral antiviral medication approved for post-exposure prophylaxis of COVID-19 globally, representing a significant advancement that...
Read more -
[Shionogi & Co., Ltd.] Nardemizin New Drug Approved in China | May 2026
Shionogi & Co., Ltd. received approval for a new drug, Nardemizin, in China, contributing to the treatment of opioid-induced constipation. The approval was granted on May 27, 2026, and further market penetration and business expansion are anticipated.
Read more -
【Shionogi & Co., Ltd.】2026 Financial Results Supplemental Materials | Sales of JPY 499.7 billion (Up 14.0% Year-over-Year)
Shionogi & Co., Ltd.'s fiscal year ending March 2026 reported sales of JPY 499.7 billion (up 14.0% YoY), operating profit is unspecified, net income increased by 21.5% to JPY 205.9 billion. Overseas sales have also grown significantly.
Read more -
【Shionogi & Co., Ltd.】2026 Fiscal Year Earnings｜Sales of ¥499.7 billion (Up 14.0% YoY)
Shionogi & Co., Ltd. achieved sales of ¥499.7 billion (14.0% increase) for the fiscal year ending March 2026, with operating profit of ¥166.7 billion (6.5% increase) and net income attributable to owners of the parent of ¥205.9 billion (20.4% increase),...
Read more -
FY2025 Financial Results Explanation Materials
In FY2025, revenue reached 499.7 billion yen (up 14.0% YoY), operating income was 166.7 billion yen (up 6.5% YoY), and net income attributable to owners of the parent was 205.2 billion yen (up 20.4% YoY), marking record highs.
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥3,475
Rating Score: 2.50 (Based on 11 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothold; and research and development of mucosal vaccines. In addition, the company provides contract support services for experimental research; contract testing of agricultural production materials; solutions for education and healthcare, system development, human resource development, and training business; marketing support services; and IT services for medical and healthcare-related issues. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Kita, Japan.
